Speciality: Oncology
Description:
In this insightful presentation, renowned oncologist Dr. Nagender Sharma delves into the evolving landscape of advanced urothelial carcinoma treatment. With a focus on evidence-based strategies, Dr. Sharma welcomes viewers to explore the latest advancements, clinical trial insights, and personalized approaches that are reshaping patient care. He emphasizes the importance of integrating immunotherapy, targeted therapies, and chemotherapy while addressing challenges like resistance mechanisms and biomarker-driven decision-making. This video serves as a comprehensive guide for clinicians seeking to optimize outcomes in this complex malignancy.
Dr. Sharma meticulously examines cutting-edge therapies such as immune checkpoint inhibitors, antibody-drug conjugates (e.g., enfortumab vedotin), and FGFR inhibitors, highlighting their roles in first-line and subsequent treatments. He discusses real-world applications of combination regimens, patient selection criteria, and the impact of molecular profiling on tailoring therapies. Additionally, he sheds light on emerging trends, including adaptive clinical trial designs and the potential of novel biomarkers to refine prognostic accuracy. His analysis balances optimism with pragmatism, acknowledging hurdles like toxicity management and access disparities.
Concluding with a forward-looking perspective, Dr. Nagender Sharma underscores the collaborative effort required to translate scientific breakthroughs into tangible survival benefits for patients. Viewers are encouraged to watch the full video to gain actionable insights and stay abreast of this rapidly advancing field. Don’t miss this opportunity to learn from a leading expert. Subscribe for future updates and deepen your understanding of oncology’s most pressing challenges.
See More Webinars @ Hidoc Webinars
1.
The clinical trial of ENZAMET shows promise as a treatment for prostate cancer.
2.
'It's rare and it's scary.' Dark spot on your fingernail could mean cancer
3.
Another KRAS Inhibitor Scores an Early Win in Advanced Non-Small Cell Lung Cancer
4.
Experts say oncology, primary care coordination necessary for best cancer patient outcomes
5.
How a California Oncologist Making $850k Spends Money
1.
Tazemetostat: A Promising New Treatment for Cancer
2.
The Converging Frontiers of Radiation Oncology and Systemic Therapies by 2025
3.
Advancing Cancer Trials: Integrating Master Protocols and Immunotherapy Guidelines
4.
Unlocking the Potential of Trabectedin: A Novel Therapy for Cancer Treatment
5.
Unlocking the Potential of Lymphocytes: Exploring the Role of These Immune System Cells
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Cost Burden/ Burden of Hospitalization For R/R ALL Patients
2.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part I
3.
An Eagles View - Evidence-based discussion on Iron Deficiency Anemia
4.
Post Progression Approaches After First-line Third-Generaion ALK Inhibitors
5.
Evolution in Treatment and Diagnosis of Lung Cancer- An Initiative from Manipal Hospitals
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation